Branded

The FDA has approved a new antibacterial drug to treat complicated UTIs.

Arakoda, the first antimalarial product approved by the Food and Drug Administration for the prevention of malaria, is being made available at select pharmacies and wholesalers.

Novartis’ Adakveo is the first targeted therapy to treat patients with a painful complication of sickle cell disease.

As part of an international collaboration, the FDA has approved AstraZeneca's new treatment option for patients with chronic lymphocytic leukemia.

The FDA has approved Xcopri, a new treatment for adults with partial-onset seizures.

Upsher-Smith has added Zembrace SymTouch injection to its savings program for patients

BeiGene USA's Brukinsa provides a treatment for patients with relapsed and refractory mantle cell lymphoma

Alnylam’s Givlaari has been approved by the FDA to treat a genetic disorder the causes buildup of toxic porphyrin molecules, which are formed during the production of heme.

Sanofi’s Fluzone High-Dose Quadrivalent is used in people age 65 and older, to protect against influenza A and B strains.

RedHill's Talicia is the first and only FDA approved rifabutin-based H. pylori infection therapy.

SB 159 authorizes pharmacists to prescribe PrEP and PEP to patient without a physician prescription and prohibits insurance companies from requiring patients to obtain prior authorization before using their insurance benefits to obtain PrEP or PEP.